The average take from a bank robbery is a bit over $4,000. Les Funtleyder , a Health Care Strategist at Miller Tabak and the author of Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services, says that even though pharma theft will likely "not be a material problem" for Lilly (on which he has a Neutral rating) and other drug companies, it must continue to take steps to ensure the security of its supply chains. "The knock on effect of pharmaceutical theft is that people could start to feel concerned about where their drugs are coming from," Funtleyder notes. "Supply chain integrity is incredibly important in the US. you need to be able to trust your drugs are what they are, that they're coming from where they're supposed to be coming from, and that they're in the condition they need to be in.". 
Share:  The average take from a bank robbery is a bit over $4,000.<span class="sent"> <span class="analyst">Les Funtleyder</span> , a Health Care Strategist at Miller Tabak and the author of Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services, says that even though pharma theft will likely "not be a material problem" for <span class="company">Lilly</span> (on which he has a Neutral rating) and other drug companies, it must continue to take steps to ensure the security of its supply chains.</span> "The knock on effect of pharmaceutical theft is that people could start to feel concerned about where their drugs are coming from," Funtleyder notes. "Supply chain integrity is incredibly important in the US. you need to be able to trust your drugs are what they are, that they're coming from where they're supposed to be coming from, and that they're in the condition they need to be in.". Tweet this 

Cowen analyst Ziad Bakri told Minyanville that '050 is clearly efficacious. Eli Lilly ( ) certainly thought so. the company paid $90 million upfront in December for the worldwide rights to ‘050, and the deal is potentially worth $665 million. "Many investors are waiting for the results of this study before assigning value to this program. 
Share:  <span class="sent">Cowen analyst <span class="analyst">Ziad Bakri</span> told Minyanville that '050 is clearly efficacious. <span class="company">Eli Lilly</span> ( ) certainly thought so.</span> the company paid $90 million upfront in December for the worldwide rights to ‘050, and the deal is potentially worth $665 million. "Many investors are waiting for the results of this study before assigning value to this program. Tweet this 

Eli Lilly and Co ( ) recently entered into a deal with Australian company, Acrux, which should help strengthen Lilly's men's health portfolio. Lilly acquired exclusive worldwide rights to commercialize Axiron, which is currently being reviewed by the US Food and Drug Administration (FDA) for the treatment of testosterone deficiency (hypogonadism) in men. As per the terms of the deal, Lilly will make an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. 
Share:  <span class="company">Eli Lilly and</span> Co ( ) recently entered into a deal with Australian company, Acrux, which should help strengthen Lilly's men's health portfolio. Lilly acquired exclusive worldwide rights to commercialize Axiron, which is currently being reviewed by the US Food and Drug Administration (FDA) for the treatment of testosterone deficiency (hypogonadism) in men. As per the terms of the deal, Lilly will make an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. Tweet this 

Erbitux, the colon cancer treatment made by Indianapolis based Lilly, can cost $40,000, said Les Funtleyder , a Miller Tabak & Co. LLC analyst in New York, in an e mail today. 
Share:  <span class="sent">Erbitux, the colon cancer treatment made by Indianapolis based <span class="company">Lilly</span>, can cost $40,000, said <span class="analyst">Les Funtleyder</span> , a Miller Tabak & Co. LLC analyst in New York, in an e mail today.</span> Tweet this 

U. S regulators delayed the approval of a new long acting diabetes drug from Amylin Pharmaceuticals ( AMLN ) and Eli Lilly ( LLY ) to finalize the medicine's label and to clarify manufacturing. While the U. S. Food and Drug Administration failed to approve Bydureon (previously known as exenatide once weekly) Friday, the agency did not ask Amylin and Lilly to conduct new clinical trials or to submit additional safety data. Amylin said it would work quickly to submit a response to the FDA's questions in the next few weeks. 
Share:  U. S regulators delayed the approval of a new long acting diabetes drug from Amylin Pharmaceuticals ( AMLN ) and Eli Lilly ( <span class="company">LLY</span> ) to finalize the medicine's label and to clarify manufacturing. While the U. S. Food and Drug Administration failed to approve Bydureon (previously known as exenatide once weekly) Friday, the agency did not ask Amylin and Lilly to conduct new clinical trials or to submit additional safety data. Amylin said it would work quickly to submit a response to the FDA's questions in the next few weeks. Tweet this 

Amylin Pharmaceuticals, Inc (NASDAQ: AMLN), Eli Lilly & Co (NYSE: LLY) and Alkermes, Inc (NASDAQ: ALKS) are still in the ‘pending' status for FDA. Evergreen Solar (NASDAQ: ESLR), Energy Conversion Devices (NASDAQ: ENER), and Dr. Pepper Snapple Group, Inc (NYSE: DPS) are all touched in Barron's. Next week we have AthenaHealth, Inc (NASDAQ: ATHN), Sequenom In.c (NASDAQ: SQNM), AMBAC Financial (NYSE: ABK), Nike Inc (NYSE: NKE), FedEx Corporation (NYSE: FDX), GameStop Corp (NYSE: GME), 3Com (NASDAQ: COMS) and Palm, Inc (NASDAQ: PALM) are all scheduled to report earnings. 
Share:  Amylin Pharmaceuticals, Inc (NASDAQ: AMLN), Eli Lilly & Co (NYSE: LLY) and Alkermes, Inc (NASDAQ: ALKS) are still in the ‘pending' status for FDA. Evergreen Solar (NASDAQ: ESLR), Energy Conversion Devices (NASDAQ: ENER), and Dr. Pepper Snapple Group, Inc (NYSE: DPS) are all touched in Barron's. Next week we have AthenaHealth, Inc (NASDAQ: ATHN), Sequenom In.c (NASDAQ: SQNM), AMBAC Financial (NYSE: ABK), Nike Inc (NYSE: NKE), FedEx Corporation (NYSE: FDX), GameStop Corp (NYSE: GME), 3Com (NASDAQ: COMS) and Palm, Inc (NASDAQ: PALM) are all scheduled to report earnings. Tweet this 

The credit card lender forecast a first quarter loss of 22 cents to 23 cents a share, after saying the company will record a pretax increase in loan loss reserves of $305 million. Eli Lilly & Co (LLY US) fell 0.2 percent to $35.74. The drugmaker was rated new "buy" at Jefferies & Co. H&R Block Inc (HRB US): The tax preparer declined 0.2 percent to $16.82. It is losing customers and may be headed for a perpetual decline, Barron's reported, citing analysts Scott Schneeberger of Oppenheimer & Co and Bill Carcache of Macquarie Securities. 
Share:  The credit card lender forecast a first quarter loss of 22 cents to 23 cents a share, after saying the company will record a pretax increase in loan loss reserves of $305 million. <span class="company">Eli</span> Lilly & Co (LLY US) fell 0.2 percent to $35.74. The drugmaker was rated new "buy" at Jefferies & Co. H&R Block Inc (HRB US): The tax preparer declined 0.2 percent to $16.82.<span class="sent"> It is losing customers and may be headed for a perpetual decline, Barron's reported, citing analysts <span class="analyst">Scott Schneeberger</span> of Oppenheimer & Co and Bill Carcache of Macquarie Securities.</span>...The credit card lender forecast a first quarter loss of 22 cents to 23 cents a share, after saying the company will record a pretax increase in loan loss reserves of $305 million. <span class="company">Eli</span> Lilly & Co (LLY US) fell 0.2 percent to $35.74. The drugmaker was rated new "buy" at Jefferies & Co. H&R Block Inc (HRB US): The tax preparer declined 0.2 percent to $16.82.<span class="sent"> It is losing customers and may be headed for a perpetual decline, Barron's reported, citing analysts <span class="analyst">Scott Schneeberger</span> of Oppenheimer & Co and Bill Carcache of Macquarie Securities.</span> Tweet this 

Four new ethics watchdogs will join Eli Lilly as part of a deal to settle two shareholder lawsuits over the mismarketing of Zyprexa and other drugs. The suits arose after Lilly inked a deal last year to end a 5 year old federal investigation into its marketing practices; that $1.4 billion deal included a $515 million fine. . According to the Indianapolis Star, Lilly will create four new positions: vice president for global compliance strategy, vice president of global ethics, senior director of enterprise risk management and a project manager to implement and monitor new ethics related policies. 
Share:  Four new ethics watchdogs will join <span class="company">Eli Lilly</span> as part of a deal to settle two shareholder lawsuits over the mismarketing of Zyprexa and other drugs. The suits arose after Lilly inked a deal last year to end a 5 year old federal investigation into its marketing practices; that $1.4 billion deal included a $515 million fine. . According to the Indianapolis Star, Lilly will create four new positions: vice president for global compliance strategy, vice president of global ethics, senior director of enterprise risk management and a project manager to implement and monitor new ethics related policies. Tweet this 

Eli Lilly ( LLY , Analyst Report ), through its animal health division, Elanco, has recently acquired the European rights to some of Pfizer's ( PFE , Analyst Report ) animal health products, consisting of vaccines, parasiticides and feed additives for both companion and production animals. In addition, Lilly will acquire a manufacturing facility in Ireland that is currently used in the production of animal vaccines. The financial details of the deal are not known. 
Share:  <span class="company">Eli Lilly</span> ( LLY , Analyst Report ), through its animal health division, Elanco, has recently acquired the European rights to some of Pfizer's ( PFE , Analyst Report ) animal health products, consisting of vaccines, parasiticides and feed additives for both companion and production animals. In addition, Lilly will acquire a manufacturing facility in Ireland that is currently used in the production of animal vaccines. The financial details of the deal are not known. Tweet this 

Amylin Pharmaceuticals, Inc (NASDAQ: AMLN) has a significant binary FDA event that will be important for Eli Lilly & Co (NYSE: LLY) and Alkermes, Inc (NASDAQ: ALKS). Patriot Coal Corporation (NYSE: PCX) is one to watch for either M&A or at least for business improvements, or for profit taking. We have a Barron's trifecta in telecom in BCE, Inc (NYSE: BCE), Mobile TeleSystems OJSC (NYSE: MBT), and QUALCOMM Inc (NASDAQ: QCOM). 
Share:  Amylin Pharmaceuticals, Inc (NASDAQ: AMLN) has a significant binary FDA event that will be important for Eli Lilly & Co (NYSE: LLY) and Alkermes, Inc (NASDAQ: ALKS). Patriot Coal Corporation (NYSE: PCX) is one to watch for either M&A or at least for business improvements, or for profit taking. We have a Barron's trifecta in telecom in BCE, Inc (NYSE: BCE), Mobile TeleSystems OJSC (NYSE: MBT), and QUALCOMM Inc (NASDAQ: QCOM). Tweet this